The Nasdaq Biotechnology index was sinking 1.6%.
In company news, Progyny (PGNY) fell more than 13% after the fertility services company reported a 99.8% year-over-year increase in Q2 to $128.7 million although that still narrowly lagged the Capital IQ consensus expecting $129.3 million in revenue for the three months ended June 30. The revenue miss also upstaged a better-than-expected Q2 earnings of $0.19 per share, reversing a $0.01 per share net loss during the same quarter last year and beating the analyst mean by $0.12 per share.
Quidel (QDEL) declined over 13% after the diagnostics company late Thursday reported non-GAAP Q2 net income of $0.75 per share, down from its $1.86 per share adjusted profit during the same quarter last year and trailing Wall Street expectations looking for non-GAAP net income of $1.19 per share.
Arena Pharmaceuticals (ARNA) was 8.9% lower after overnight reporting a Q2 net loss of $2.40 per share, missing analyst expectations for a $2.17 per share net loss. The drug maker generated no revenue during the three months ended June 30, also lagging the $740,000 Street view.
|Insider Sell: Neurocrine Biosciences|
|Sonoco Completes Acquisition of Ball Metalpack for $...|
|Insider Sell: Intuitive Surgical|
|Market Chatter: Tencent Reportedly Plans to Take Dou...|
|SMBC Nikko Securities Starts DLocal at Neutral With ...|